Alumis’ Phase III TYK2 data intensify psoriasis efficacy contest

Alumis has proposed a $175 million follow-on financing after reporting top-line Phase III data that put its TYK2 inhibitor, envudeucitinib, in the running for best-in-class efficacy in plaque psoriasis, although full data will be needed to evaluate that possibility. The company plans to submit an NDA in 2H26.

Alumis Inc. (NASDAQ:ALMS) said Tuesday that twice-daily envudeucitinib met the co-primary endpoints of static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75 at 16 weeks in the 840-patient Phase III Onward1 and Onward2 clinical trials. The candidate also met the secondary endpoints of PASI 90 and PASI 100 at 24 weeks. ...